X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, SQZ Biotechnologies will regain full clinical development and future commercialization rights for its programs including, SQZ-eAPC-HPV, based on antigen presenting cells (APCs) created by the SQZ platform and targeting HPV 16 positive tumors.
Lead Product(s): SQZ-eAPC-HPV,Pembrolizumab
Therapeutic Area: Oncology Product Name: SQZ-eAPC-HPV
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,375.0 million Upfront Cash: $125.0 million
Deal Type: Collaboration July 25, 2023
Details:
SQZ-AAC-HPV are derived from RBCs engineered with the Cell Squeeze® technology, designed to take advantage of the natural physiological process of aged RBC clearance by resident APCs in lymphoid organs which primes endogenous T cells to potentially drive antitumor activity.
Lead Product(s): SQZ-AAC-HPV,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: SQZ-AAC-HPV
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
The SQZ® eAPC platform is the company’s second-generation cell therapy platform which simultaneously delivers five different mRNAs—each encoding for a different protein which plays a part in stimulating key T cell activation signals.
Lead Product(s): SQZ-eAPC-HPV,Pembrolizumab
Therapeutic Area: Oncology Product Name: SQZ-eAPC-HPV
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
SQZ-eAPC-HPV are derived from PBMCs, which are primarily composed of monocytes, T cells, B cells, and NK cells, and engineered with various mRNA encoding for multiple target antigens and immuno-stimulatory signals, including CD86 and membrane-bound IL-2 and IL-12.
Lead Product(s): SQZ-eAPC-HPV,Pembrolizumab
Therapeutic Area: Oncology Product Name: SQZ-eAPC-HPV
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Data, published in Frontiers in Immunology, demonstrated that Cell Squeeze® SQZ-AAC platform can be used to generate AACs by engineering RBCs with antigen and adjuvant that can drive antigen-specific activation of T cells both in mouse in vivo and human in vitro systems.
Lead Product(s): SQZ-AAC
Therapeutic Area: Oncology Product Name: SQZ-AAC
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
SQZ-APC-HPV (SQZ-PBMC-HPV) is company’s APC autologous cell therapy clinical candidate and is derived from peripheral blood mononuclear cells, primarily composed of monocytes, T cells, B cells, and NK cells, and engineered tumor specic E6 and E7 peptide antigens.
Lead Product(s): SQZ-PBMC-HPV,Atezolizumab
Therapeutic Area: Oncology Product Name: SQZ-APC-HPV
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
SQZ-PBMC-HPV is an autologous cell therapy candidate comprised of SQZ-engineered antigen presenting cells (APCs) designed to induce CD8 T cell responses against HPV16.
Lead Product(s): SQZ-PBMC-HPV,Nivolumab
Therapeutic Area: Oncology Product Name: SQZ-PBMC-HPV
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
SQZ-PBMC-HPV is being evaluated in a Phase 1/2 clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors. Patients must be positive for the human leukocyte antigen serotype HLA-A*02.
Lead Product(s): SQZ-PBMC-HPV,Atezolizumab,Ipilimumab
Therapeutic Area: Oncology Product Name: SQZ-PBMC-HPV
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
The data published, demonstrated that TACs can induce multiple key mechanisms of antigen-specific tolerance in various model systems, including deletion of autoreactive T cells, energy, and expansion of regulatory T cells capable of bystander suppression.
Lead Product(s): RBC-derived Engineered Cell Therapy
Therapeutic Area: Endocrinology Product Name: SQZ TACs
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
With the support of the NIH grant, and building upon our experience in multiplex engineering of immune cells, SQZ researchers will attempt to generate dopaminergic neurons directly from somatic cells.
Lead Product(s): Allogeneic Cell Replacement Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
